The orphan drug market is continuously growing over the years now at twice the growth rate of overall prescription drug market due to the arising interest from pharmaceutical companies for underlying benefits and involvement of many smaller biotechnology start-up companies who are primarily focused on rare diseases. However still there are lot of attention that needs to be given since the ratio of one having rare disease is 1 in 2000 leading to the lack of knowledge about disease mechanisms, along with FDA/Marketing approvals which take years.
The goal of this Conference is uniting all well-known clinical researchers, biotech professionals, Medical Advisories, Academicians and decision makers to discuss possible ways to accelerate orphan drug development and access to rare disease patients, including the introduction of recent technologies and products to help aid the access of orphan drugs.
In the pioneer edition of DBMR Conference on Rare Disease and Orphan Drugs come join us in this enriching knowledge fest where experts will speak on new technologies and market dynamics perceptions. Together let’s move ahead in the future of medical science and technology.
Founder, Regulatory Specialist (ODD, Fast Track, Breakthrough, RMAT)
KLA Breakthrough Consulting